AVITA Medical, Inc.RCELNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-26.75%
↓ 200% below average
Average (39q)
26.86%
Historical baseline
Range
High:827.74%
Low:-90.49%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -26.75% |
| Q2 2025 | -18.57% |
| Q1 2025 | 29.57% |
| Q4 2024 | -10.65% |
| Q3 2024 | 11.07% |
| Q2 2024 | -5.91% |
| Q1 2024 | -23.22% |
| Q4 2023 | 53.96% |
| Q3 2023 | -13.44% |
| Q2 2023 | 10.68% |
| Q1 2023 | 35.72% |
| Q4 2022 | -11.06% |
| Q3 2022 | 24.19% |
| Q2 2022 | -15.50% |
| Q1 2022 | -13.77% |
| Q4 2021 | 23.91% |
| Q3 2021 | -14.75% |
| Q2 2021 | -3.29% |
| Q1 2021 | 22.26% |
| Q4 2020 | -0.39% |
| Q3 2020 | 83.87% |
| Q2 2020 | -26.45% |
| Q1 2020 | 7.92% |
| Q4 2019 | -4.56% |
| Q3 2019 | 55.80% |
| Q2 2019 | 9.28% |
| Q1 2019 | -42.94% |
| Q4 2018 | -2.54% |
| Q3 2018 | 827.74% |
| Q2 2018 | -90.49% |
| Q1 2018 | 46.89% |
| Q4 2017 | -0.50% |
| Q3 2017 | 37.50% |
| Q2 2017 | 0.60% |
| Q1 2017 | 57.89% |
| Q4 2016 | -5.73% |
| Q3 2016 | 35.48% |
| Q2 2016 | -3.07% |
| Q1 2016 | 30.08% |
| Q4 2015 | 3.59% |